NHWA(SZ:002262)2025-03-28 10:25Financial Performance - The company's operating revenue for 2024 reached ¥5,697,633,044.59, representing a 13.01% increase compared to ¥5,041,504,467.27 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥1,143,564,427.44, up 10.28% from ¥1,036,918,058.61 in 2023[6]. - The basic earnings per share for 2024 increased to ¥1.13, a rise of 9.71% from ¥1.03 in 2023[6]. - Total assets at the end of 2024 amounted to ¥8,440,005,655.95, reflecting a 15.17% growth from ¥7,328,195,368.67 at the end of 2023[6]. - Operating profit reached ¥1,336,573,612.01, while total profit amounted to ¥1,296,688,433.42, reflecting increases of 13.04% and 10.96% respectively compared to the previous year[49]. - The company achieved a total revenue of ¥5,697,633,044.59 for the fiscal year 2024, representing a year-on-year growth of 13.01%[49]. - The industrial segment contributed ¥4,823,256,135.4, accounting for 84.65% of total revenue, with a year-on-year growth of 14.29%[81]. - Domestic sales amounted to ¥5,614,741,828.0, which is 98.55% of total sales, reflecting a 13.04% increase from the previous year[82]. - International sales surged by 162.53% to ¥23,285,928.63, up from ¥8,869,818.05 in 2023[82]. - The gross profit margin for the industrial segment was 82.77%, with a year-on-year increase of 0.68%[82]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 3.60 CNY per 10 shares to all shareholders, based on a total of 1,016,176,792 shares[3]. - The cash dividend amount for the reporting period is 365,823,645.12 CNY, with a per-share dividend of 3.60 CNY[167]. - The total distributable profit for the parent company is 5,629,861,031.98 CNY, with the cash dividend accounting for 100% of the profit distribution[167]. - The company has not made any adjustments to its cash dividend policy during the reporting period, adhering strictly to the established policy[167]. - The company plans to distribute a cash dividend of 3.60 CNY per 10 shares, totaling approximately 365,823,645.12 CNY, which represents 31.99% of the net profit attributable to shareholders for the year 2024[169]. Research and Development - The company is expected to continue focusing on innovation and R&D in response to the pressures from volume-based procurement policies[30]. - The company increased its R&D investment in innovative drugs, with a total expenditure of 721 million yuan, representing a 17.48% increase compared to the previous year[42]. - There are currently over 70 ongoing research projects, including 14 innovative drug projects, with 1 project having completed Phase III clinical trials[42]. - The company applied for 50 invention patents and received 19 authorized patents, including 10 overseas patents[43]. - The company has established a leading R&D platform for high-end drug delivery systems, addressing issues such as patient compliance and addiction[54]. - The company is actively promoting product sales and enhancing business development collaborations in the CNS therapeutic area[43]. Market Position and Strategy - The company is positioned in the pharmaceutical industry, which is experiencing rapid growth due to increasing health demands and an aging population[29]. - The company is a key producer and seller of central nervous system drugs in China, with a unique focus on R&D and production in this field[35]. - The company is the only listed enterprise in China dedicated to the R&D and production of central nervous system drugs, providing a competitive edge[35]. - The company aims to become a leading manufacturer and supplier of central nervous system drugs in China and a significant global production base by 2025[114]. - The company is focusing on unmet clinical needs in the central nervous system field, aligning with national health strategies and policies[51]. Challenges and Risks - The company faces challenges from ongoing healthcare reforms and policies aimed at controlling medical costs, which may impact profitability[30]. - The company must invest substantial funds annually in drug research and development, with the risk of extended development cycles due to stricter national regulations[125]. - Environmental risks are present due to potential pollution from wastewater and waste gas during production, which could affect surrounding communities[125]. - The company faces risks from industry policy changes, including drug approval, quality supervision, and medical insurance cost control, which could significantly impact future development[125]. Corporate Governance and Management - The company has established a long-term mechanism to prevent major shareholders from occupying company funds, ensuring the protection of shareholder rights[132]. - The board of directors consists of four independent directors, exceeding one-third of the total board, ensuring compliance with governance standards[132]. - The company has a complete and independent financial management system, ensuring no interference from controlling shareholders in financial decisions[138]. - The company actively engages in charitable activities, enhancing its social image and fulfilling corporate social responsibilities[135]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and managers, ensuring compliance with legal regulations[136]. Environmental Management - The company has established a comprehensive environmental management system and has passed ISO 14001 certification, complying with various environmental standards[187]. - The company invested approximately 5.6 million yuan in 2022 to upgrade its wastewater pre-treatment system, resulting in improved operational stability and reduced use of hazardous chemicals[192]. - The company’s wastewater treatment system has a capacity of 600t/d, with all monitoring results indicating compliance with discharge standards[192]. - The company’s air pollution control system was upgraded in 2021, adding four new systems to improve overall efficiency[193]. - The company allocated approximately 12.34 million yuan for environmental protection and equipment upgrades during the reporting period[198].